CooperVision presents new research findings on contact lenses at GSLS 2025

Image credit: AdobeStock/Svitlana

CooperVision presented new contact lens research in 2 scientific poster presentations at the 2025 Global Contact Len Symposium (GSLS), which ran from January 15-18 in Las Vegas, Nevada.¹ The posters presented research conducted on the optical design used in MyDay Energys and Biofinity Energys brands for digital device users, in addition to CooperVision’s Binocular Progressive System for presbyopes utilized in the MyDay and clariti 1 day product families, according to a news release.

“While we conduct and support a sizable range of foundational studies every year, we also prioritize research that helps eye care professionals (ECPs) have a deeper understanding of how the contact lenses they fit everyday work in practice on their patients. This helps support confidence among prescribers, ideal patient experiences, and practice success. It’s the type of practical scientific evidence that the profession has come to expect from a partner like CooperVision,” said Francis Erard, CooperVision’s vice president of Research & Development, in the release.

In the poster “Influence of Pupil Size on Vision Performance and Visual Satisfaction with a Daily Disposable Multifocal Contact Lens System,” 45 participants with varied pupil sizes (2.3 mm at 250cd/m2 to 6.6 mm at 2.5cd/m2) were fit into MyDay daily disposable multifocal contact lenses, also outfitted with the Binocular Progressive System.¹ Distance binocular high contrast visual acuity (BHCVA) under high and low illumination, distance binocular low contract visual acuity (BLCVA) measured under high illumination, near BHCVA and near BHLCA under medium illumination, and subjective vision satisfaction scores at distance and near were all measured in the clinical study.¹

No significant correlations were found between visual acuity and pupil size across varying degrees of distance, contrast, and luminance. Correlations were either weak or very weak between vision metrics, including visual acuity and vision satisfaction, and pupil size, in every environmental condition.¹ Thus, the Binocular Progression System effectively corrects for presbyopia independent of pupil size, which supports MyDay multifocal and clariti 1 day multifocal as an option for eye care providers to fit with a wide variety of patients, according to the release.

Additionally, the “Comparison of Axial Eye Growth in Children Undergoing Orthokeratology to Myopic Eye Growth” poster presented analysis of real world retrospective axial length (AL) data from 429 patients 6-19 years old who wore overnight orthokeratology contact lenses (Paragon CRT 100 and Paragon CRT Dual Axis). Data for the study was collected from the Berkeley Myopia Control Clinic between 2008 and 2023.¹ Analysis of said data found eye growth among patients was slower than expected if left untreated, with rates approximately half compared to anticipated progression of adolescent eyes (11-18 years old) and slightly greater than 50% in younger eyes (6-10 years old). Lens treatment effects were similar between the Paragon CRT 100 and Paragon CRT Dual Axis.¹

“The caliber of eye care is constantly increasing around the globe, as are expectations among patients and ECPs alike. CooperVision believes that reinforcing everyday clinical decisions with sound evidence will continue to become more critical, and why we are dedicated to advancing ocular science through the research we conduct and support though our partnerships,” said Erard in the release.

Reference:

1. GSLS 2025 posters highlight CooperVision major scientific breakthroughs. News release. CooperVision. January 15, 2025. Accessed January 28, 2025. https://coopervision.com/our-company/news-center/press-release/gsls-2025-posters-highlight-coopervision-major-scientific